BRIEF published on 12/19/2025 at 12:05, 7 months 23 days ago Biotest AG Announces FDA Approval of Grifols' Fesilty™ FDA Approval Biotest AG U.S. Market Grifols Fibrinogen Therapy
PRESS RELEASE published on 12/19/2025 at 12:00, 7 months 23 days ago Biotest announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) Biotest AG announces US FDA approval of Grifols’ Fesilty™ (fibrinogen, human-chmt) for acute bleeding episodes in patients with fibrinogen deficiency Biotest AG Fibrinogen Grifols US FDA Approval Fesilty
BRIEF published on 11/13/2025 at 10:12, 8 months 28 days ago Biotest Obtains Approval for Prufibry® in Germany Clinical Trials Biotest AG German Market Prufibry® Approval Fibrinogen Deficiency
PRESS RELEASE published on 11/13/2025 at 10:07, 8 months 28 days ago Biotest obtains approval for new human fibrinogen Prufibry® in Germany Biotest AG obtains approval in Germany for new human fibrinogen Prufibry®, expanding intensive care and coagulation factor portfolio with a life-saving therapy for congenital and acquired fibrinogen deficiency Germany Biotest AG Approval Human Fibrinogen Prufibry
BRIEF published on 11/07/2025 at 15:24, 9 months 4 days ago Biotest AG Schedules Extraordinary General Meeting at Grifols' Request Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
PRESS RELEASE published on 11/07/2025 at 15:19, 9 months 4 days ago Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A. Biotest AG convenes an extraordinary general meeting at the request of Grifols S.A. to discuss changing its legal form to a partnership limited by shares (KGaA) on 17 December 2025 Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
BRIEF published on 10/23/2025 at 13:21, 9 months 19 days ago Biotest AG Cancels Extraordinary General Meeting Grifols S.A. Extraordinary General Meeting Legal Form Change Corporate Restructuring Biotest AG News
PRESS RELEASE published on 10/23/2025 at 13:16, 9 months 19 days ago Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025 Biotest AG cancels extraordinary general meeting scheduled for 28 October 2025 following withdrawal of convocation request by Grifols S.A Grifols S.A. Cancellation Extraordinary General Meeting Biotest AG Legal Form Change
BRIEF published on 10/09/2025 at 17:35, 10 months 2 days ago Biotest's Yimmugo® Enters the U.S. Market Biotest AG U.S. Market Yimmugo® Launch Primary Immunodeficiencies Plasma-derived Medicines
PRESS RELEASE published on 10/09/2025 at 17:30, 10 months 2 days ago Biotest’s Yimmugo® launches in the United States Biotest AG launches Yimmugo®, a polyvalent human normal immunoglobulin (IVIg) for primary immunodeficiencies in the U.S., marking a significant milestone for the company's global growth strategy Biotest AG Yimmugo U.S. Launch Primary Immunodeficiencies IVIg
Published on 08/12/2026 at 00:00, 7 hours 20 minutes ago Organto Foods Reports Record Second Quarter 2026 Financial Results
Published on 08/11/2026 at 23:40, 7 hours 40 minutes ago RJK Explorations Ltd. Announces Private Placement for Gross Proceeds of up to $100,000
Published on 08/11/2026 at 23:15, 8 hours 5 minutes ago Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador
Published on 08/11/2026 at 23:00, 8 hours 20 minutes ago Prospectiva Resources Ltd. Completes Qualifying Transaction
Published on 08/11/2026 at 22:55, 8 hours 25 minutes ago NV Gold Announces Non-Brokered Private Placement
Published on 08/12/2026 at 07:00, 20 minutes ago MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor
Published on 08/12/2026 at 07:00, 20 minutes ago SCHOTT Pharma with strong third quarter and on track for planned growth
Published on 08/12/2026 at 07:00, 20 minutes ago TUI delivered resilient Q3 underlying EBIT of €234.6m (at CC), demonstrating the strength of its business despite geopolitical headwinds and one-offs, FY26 guidance reaffirmed
Published on 08/12/2026 at 07:00, 20 minutes ago E.ON remains on track and continues to invest in the energy transition
Published on 08/12/2026 at 07:00, 20 minutes ago Subdued demand weighs on Hawesko's business in the first half of the year – gross profit margin up – cost and efficiency progress taking effect – full-year 2026 guidance adjusted
Published on 08/10/2026 at 18:00, 1 day 13 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 1 day 19 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 1 day 19 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 1 day 21 hours ago Number of shares and voting rights - July 2026 (In French only)
